DB
ASBPW

Dmitry Balyasny’s Aspire Biopharma Warrant ASBPW Stock Holding History

Dmitry Balyasny’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200,000
Closed -$8.36K – 2893
2023
Q1 		$8.36K Hold
200,000
– – ﹤0.01% 2504
2022
Q4 		$16K Hold
200,000
– – ﹤0.01% 2509
2022
Q3 		$29K Hold
200,000
– – ﹤0.01% 2536
2022
Q2 		$24K Buy
+200,000
New +$43.5K ﹤0.01% 2457

Other funds holding ASBPW

MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return

Dmitry Balyasny's ASBPW Position: Q2 2023 in Review

Dmitry Balyasny sold out of Aspire Biopharma Warrant (ASBPW) in Q2 2023, closing a stake of 200,000 shares — an estimated $8.36K sold.

Dmitry Balyasny first reported a position in ASBPW in Q2 2022 and held it in 4 quarters. The position peaked at $29K in Q3 2022. 40 funds tracked by Wall St. Rank hold ASBPW as of Q2 2023.

  • Dmitry Balyasny reported no remaining Aspire Biopharma Warrant position as of Q2 2023 after selling out during the quarter.
  • Dmitry Balyasny sold 200,000 Aspire Biopharma Warrant shares in Q2 2023, an estimated $8.36K.
  • Dmitry Balyasny first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 4 quarters.
  • Dmitry Balyasny's Aspire Biopharma Warrant position peaked at $29K in Q3 2022.
  • 40 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.